Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 2Spondylitis, Ankylosing 1Signs and Symptoms 1Psoriasis 1Nutrition Disorders 1Lymphoma 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Inflammatory Bowel Diseases 1Glioma 1Gastroparesis 1Feeding and Eating Disorders 1Esophageal Neoplasms 1Epilepsy 1Dumping Syndrome 1Diarrhea 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Fluorouracil 498Bevacizumab 476Oxaliplatin 450Leucovorin 442Irinotecan 408Cetuximab 318Capecitabine 317pembrolizumab 142Folfox protocol 128Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 82IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 47Standard of Care 45Neoadjuvant Therapy 45Magnetic Resonance Spectroscopy 44Biopsy 44Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 39Cyclophosphamide 39Surveys and Questionnaires 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Sulfasalazine × Clear all
NCT06134388 2023-11-18

Sulfasalazine in Patients With Metastatic Colorectal Cancer

Tanta University

Phase 3 Recruiting
50 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡